Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| + | *[[Media:2017_11-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21, 2017]] | ||
*[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] | *[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] | ||
*[[Media:2017_09-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 29, 2017]] | *[[Media:2017_09-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 29, 2017]] | ||
| − | |||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 20:40, 16 January 2018
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Weinmann
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive